[1] Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X, He J (2018) Cancer incidence and mortality in China, 2014. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 30 (1):1-12
[2] Chen H, Chi P, Wang W, Li L, Luo Y, Fu J, Zhang L, Liu W (2014) Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 25:110-115
[3] Chen H, Chen S, Lu J, Wang X, Li J, Li L, Fu J, Scheper T, Meyer W, Peng YH, Liu W (2017) Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China. Cancer Prev Res (Phila) 10 (9):542-550
[4] Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M (2012) Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. International journal of cancer 131 (2):406-416
[5] Henle G, Henle W (1976) Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. International journal of cancer 17 (1):1-7
[6] Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS (2001) Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. The New England journal of medicine 345 (26):1877-1882
[7] Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR (1982) Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. International journal of cancer 29 (2):139-141
[8] Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, Liang JS, Qiu H (1992) Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69 (1):3-7
[9] Chen Y, Xin X, Cui Z, Zheng Y, Guo J, Lin Y, Su G (2016) Diagnostic Value of Serum Epstein-Barr Virus Capsid Antigen-IgA for Nasopharyngeal Carcinoma: a Meta-Analysis Based on 21 Studies. Clinical laboratory 62 (6):1155-1166
[10] Li S, Deng Y, Li X, Chen QP, Liao XC, Qin X (2010) Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chinese medical journal 123 (9):1201-1205
[11] Ling W, Cao SM, Huang QH, Li YH, Deng MQ (2009) Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong. Ai zheng = Aizheng = Chinese journal of cancer 28 (1):57-59
[12] Zeng Y (1985) Seroepidemiological studies on nasopharyngeal carcinoma in China. Advances in cancer research 44:121-138
[13] Cao SM, Liu Z, Jia WH, Huang QH, Liu Q, Guo X, Huang TB, Ye W, Hong MH (2011) Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PloS one 6 (4):e19100
[14] Du JL, Chen SH, Huang QH, Xie SH, Ye YF, Gao R, Guo J, Yang MJ, Liu Q, Hong MH, Cao SM (2016) Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study. Chinese journal of cancer 35 (1):78
[15] Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM (2005) Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. Journal of medical virology 75 (4):593-602
[16] Gao R, Wang L, Liu Q, Zhang LF, Ye YF, Xie SH, Du JL, Chen SH, Guo J, Yang MJ, Lin CY, Cao SM (2017) Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case-control trial. BMJ open 7 (6):e013211
[17] Wu X, Chao Y, Wan Z, Wang Y, Ma Y, Ke P, Xu J, Zhuang J, Huang X (2016) A comparative evaluation of the analytical performances of Capillarys 2 Flex Piercing, Tosoh HLC-723 G8, Premier Hb9210, and Roche Cobas c501 Tina-quant Gen 2 analyzers for HbA1c determination. Biochemia medica 26 (3):353-364
[18] Grandjean Lapierre S, Vallieres E, Rabaamad L, Labrecque M, Chartrand C, Renaud C (2016) Evaluation of the abbot Architect() epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 81:1-5
[19] Francois C, Segard C, Bouvier M, Stefanski M, Pannier C, Zawadzki P, Roussel C, Hecquet D, Duverlie G, Brochot E, Castelain S (2018) Comparison of Abbott Architect((R)), Siemens Immulite((R)), and Diasorin Liaison((R)) for determination of Epstein-Barr virus serological diagnosis. Diagnostic microbiology and infectious disease 90 (2):96-101
[20] de-Vathaire F, Sancho-Garnier H, de-The H, Pieddeloup C, Schwaab G, Ho JH, Ellouz R, Micheau C, Cammoun M, Cachin Y, et al. (1988) Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. International journal of cancer 42 (2):176-181
[21] Lynn TC, Tu SM, Kawamura A, Jr. (1985) Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. The Journal of laryngology and otology 99 (6):567-572
[22] Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, Chua DT, Sham JS, Ng MH (2007) Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. British journal of cancer 96 (4):623-630
[23] Liu MT, Yeh CY (1998) Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Radiation medicine 16 (2):113-117
[24] Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, Zhou GQ, Cheng ZB, Qi ZY, Sun Y (2017) Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Cancer science 108 (8):1640-1647
[25] Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J, Li MY, Chen LZ, Feng QS, Jia WH, Zeng YX (2008) Evaluation of a multianalyte profiling assay and an enzyme-linked immunosorbent assay for serological examination of Epstein-Barr virus-specific antibody responses in diagnosis of nasopharyngeal carcinoma. Clinical and vaccine immunology : CVI 15 (11):1684-1688
[26] de Ory F, Guisasola ME, Sanz JC, Garcia-Bermejo I (2011) Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clinical and vaccine immunology : CVI 18 (3):444-448